Onco-Innovations Limited (NEO:ONCO)

Market Cap	38.25M -61.5%
Revenue (ttm)	110.38K +69.1%
Net Income	-10.78M
EPS	-0.19
Shares Out	68.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,172
Open	0.5500
Previous Close	0.5600
Day's Range	0.5500 - 0.5800
52-Week Range	0.3500 - 1.9800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 14, 2026

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3′-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Thomas O’Shaughnessy
• Employees: 1
• Stock Exchange: Cboe Canada
• Ticker Symbol: ONCO

Financial Performance

In fiscal year 2026, Onco-Innovations's revenue was 110,378, an increase of 69.06% compared to the previous year's 65,291. Losses were -10.78 million, 42.5% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error